Perhaps - but amgen already have the market.
Imagine how Amgen's shareholders would feel in 3 years when another one of their revenue streams flounders due to the inaction of management after being publicly called out by a relatively unknown asx bio. It's worth noting that carfilzomib's revenue has increased recently due to combination treatment with Darzalex (J&J).
Do we know anyone from J&J?
General Comments / Chat, page-4984
-
- There are more pages in this discussion • 6,245 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.62 |
Change
0.015(0.93%) |
Mkt cap ! $276.0M | |||
| Open | High | Low | Value | Volume |
| $1.69 | $1.69 | $1.55 | $456.4K | 284.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $1.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.62 | 2659 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |